http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 08:13:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html si-local-file:///var/storage/secattach/20260820/26953324.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+20/26953324.html Thu, 20 Aug 2026 08:13:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Press+Releases/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html <ul type="disc"><li style="text-align:justify;"><em>Revenue for the first half of 2026 increased 29%</em> <em>year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. </em></li><li style="text-align:justify;"><em>Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer </em></li><li style="text-align:justify;"><em>Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA</em></li><li style="text-align:justify;"><em>Chinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026<br/><br/></em></li></ul> http://www.streetinsider.com/Globe+Newswire/Ascentage+Pharma+Reports+2026+Interim+Unaudited+Financial+Results+and+Provides+Business+Updates/26951506.html Wed, 19 Aug 2026 19:00:00 -0400 36X 6855 A.06822034 A.12314189 A.16793667 AAPG O.00000526 O.20026344 O.20314276 O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+13/26935703.html si-local-file:///var/storage/secattach/20260817/26935703.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+13/26935703.html Mon, 17 Aug 2026 09:01:00 -0400 36X AAPG O.38659577 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+13/26935703.html si-local-file:///var/storage/secattach/20260817/26935703.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ASCENTAGE+PHARMA+GROUP++++For%3A+Aug+13/26935703.html Mon, 17 Aug 2026 09:01:00 -0400 36X AAPG O.38659577